Small molecule inhibitors of the ERK1/2 pathway have been approved for the treatment of BRAFV600E metastatic melanoma and other inhibitors of MAP kinase pathways are undergoing clinical evaluation. The gene discussed is MAPK3; the disease is metastatic melanoma.